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. Three major causes of these problems are incomplete tumour targeting, inadequate tissue penetration and limited toxicity to all cancer cells [1] [2] [3] . These drawbacks prevent effectual treatment and are associated with increased morbidity and mortality.
Using a top-down engineering approach, the ideal cancer therapy can be envisioned: it would be tiny programmable 'robot factories' (FIG. 1a) that specifically target tumours, are selectively cytotoxic to cancer cells, are self-propelled, are responsive to external signals, can sense the local environment and are externally detectable. Specific targeting would allow the use of more toxic molecules without systemic effects. Self-propulsion would enable penetration into tumour regions that are inaccessible to passive therapies. Responsiveness to external signals would enable the precise control of the location and timing of cytotoxicity. Sensing the local environment would allow 'smart' , responsive therapies that can make decisions about where and when drugs are administered. Finally, the ability to be externally detected would provide crucial information about the state of the tumour, the success of localization and the efficacy of treatment.
Bacteria can be viewed as these perfect robot therapies because they have biological mechanisms to carry out all of the ideal functions mentioned above (FIG. 1b) . Over the past century, many genera of bacteria have been shown to preferentially accumulate in tumours, including Salmonella 4 , Escherichia 5 , Clostridium 6, 7 and Bifidobacterium 8 . Caulobacter 9 , Listeria 10, 11 , Proteus 12 and Streptococcus 13 have also been investigated as anticancer agents. For propulsion and sensing, bacteria have flagella that enable tissue penetration 14 and chemotactic receptors that direct chemotaxis towards molecular signals in the tumour microenvironment 15, 16 . For example, the TAR receptor detects aspartate secreted by viable cancer cells, and the TRG receptor promotes migration towards ribose in necrotic tissue 16 . Selective cytotoxicity can be engineered by transfection with genes for therapeutic molecules, including toxins [17] [18] [19] , cytokines 20, 21 , tumour antigens 22 and apoptosis-inducing factors [23] [24] [25] [26] [27] . External control can be achieved using gene promoter strategies that respond to small molecules 17, 28, 29 or radiation 23, 26, 27, 30 . Bacteria can be detected using light 5, 31, 32 , magnetic resonance imaging (MRI) 33 and positron emission tomography (PET) [34] [35] [36] . Finally, and most importantly, the ease of genetically manipulating bacteria is the feature that will have the greatest effect on therapy development because it enables precise tuning and limitless functional combinations.
Once fully implemented and tested, the unique capabilities of bacterial therapies will change the way cancer is treated. The manufacture of drugs in tumours would beneficially shift temporal drug concentration profiles compared with intravenous administration (FIG. 2) . Because bacteria can migrate and accumulate far from the vasculature, more of the therapeutic would be present in distal regions for longer periods of time compared with small molecules that diffuse only passively. Intratumoural production would be more toxic to cancer tissue and less toxic to normal tissue. This inversion of drug localization would eliminate tumours from the inside out, and would have the simultaneous effects of increasing efficacy and decreasing damage to normal tissue.
To date, many different bacterial strategies have been implemented in animal models (TABLES 1, 2) and some human trials have been carried out (TABLE 3) . Using these strategies, many researchers have observed experimental success, with reduced tumour volume and increased survival and treatment of metastatic disease (TABLE 1) . Success has also been shown in treating multiple tumour sites (TABLE 1) ; the most notable is pancreatic cancer 13, 37 , for which new targeted treatments could dramatically improve the poor current prognosis of less than 25% 5-year survival. Since the mid-1990s, the number of published bacterial therapy papers has increased, with a doubling time of 2.5 years (FIG. 1c) . This rapid rise has been driven almost entirely by the increasing use of Salmonella as a delivery vector (FIG. 1c) . This Innovation article describes many of the advances that have fuelled this enthusiasm, including specific bacterial targeting of tumours; intratumoral penetration; native bacterial cytotoxicity; expression of anticancer agents; gene-triggering strategies; and detection of bacterial therapies. Nature Reviews | Cancer Bacterial targeting of tumours One of the major advantages of bacterial therapies for cancer is the ability to specifically target tumours. The mechanisms of bacterial accumulation in tumours differ depending on oxygen tolerance. Obligate anaerobes (for example, Clostridium and Bifidobacterium) cannot survive in oxygen, and injected bacterial spores can only germinate in the anoxic regions of tumours 38, 49 . Completely deoxygenated tissue is unique to tumours and is not present in most other organs of the body. Obligate anaerobes are therefore highly effective at accumulating in the large hypoxic regions of tumours 14 . This absolute specificity was demonstrated by Malmgren et al. 7 who injected Clostridium into tumour-bearing mice and showed that only the mice with tumours died from this infection.
Facultative anaerobes (for example, Salmonella and Escherichia) use a more complex set of mechanisms to target tumours. Five interacting mechanisms are thought to control the accumulation of facultative anaerobes in tumours: entrapment of bacteria in the chaotic vasculature of tumours 40 ; flooding into tumours following inflammation 41 ; chemotaxis towards compounds produced by tumours 15, 16 ; preferential growth in tumour-specific microenvironments 15, 31 ; and protection from clearance by the immune system 42 . These mechanisms enable Salmonella to accumulate in tumours at ratios greater than 1000/1 compared with organs that are rich in reticuloendothelial cells (such as the liver and spleen) and Salmonella accumulate at even greater ratios in other organs 40, [43] [44] [45] . when injected systemically, Salmonella attach to the walls of tumour vasculature with a low but measurable frequency (~0.035% of bacteria in the blood) 40 . In addition, the number of bacteria that adheres is dependent on blood velocity, suggesting that haemodynamics have an important role in the initial interaction of bacteria with tumours 40 . Similarly, the accumulation of Salmonella is associated with an influx of blood into tumours, caused by an immunologically induced rise in the blood concentration of tumour necrosis factor-α (TnFα) 41 . This mechanism would be reduced for attenuated msbB -strains that elicit much lower (~10%) TnFα levels 46 . The production of TnFα immediately after injection therefore has contradictory effects: it promotes accumulation in tumours but is also the primary cause of bacterial toxicity owing to septic shock 46 . This dependence on an immune response to promote targeting could also reduce the usefulness of repeated dosing with bacteria, which is a limitation that does not affect bacteria that are delivered as spores 47 .
In in vitro tumour models, Salmonella identify and penetrate tumours by detecting and chemotaxing towards small molecule gradients of serine, aspartate and ribose 15, 16 . In addition, the growth rate of Salmonella is greater in in vitro tumours when dying cells are present 15 , a phenomenon which is also observed in animal tumour models 40, 41, 46 . The importance of this mechanism for promoting accumulation is supported by the increased tumour specificity of auxotrophic Salmonella that require leucine and arganine, which are nutrients derived from dying tumour tissue 31, 48 . Because tumours are immune-privileged environments 49 , bacteria can replicate unimpeded by the macrophage and neutrophil clearance mechanisms that normally serve to eliminate them 50 . In this way, the immune system has a complicated role in bacteriolytic therapy: it provides a mechanism to guide bacterial accumulation, but also impedes dispersion and efficacy. The interaction between bacteria and the immune system also works in reverse: many bacterial therapies sensitize the immune system to induce tumour clearance 51, 52 .
Intratumoral penetration
Intratumoral targeting is an essential characteristic of an optimized cancer therapy (FIG. 1) . Compared with normal tissue, tumours have chaotic vasculature and large intercapillary distances, which impede the delivery of therapeutic molecules 3, 53 . This reduces therapeutic efficacy by creating cellular regions that have low drug concentrations and reduced nutrient supply 1, 3 . low levels of oxygen and glucose create quiescent cells that are unresponsive to chemotherapeutics that are designed to target rapidly growing cells. Proper intratumoral targeting enables direct drug delivery to these distal, unresponsive cells that are far from the tumour vasculature (FIG. 2) . In this way, the metabolic heterogeneity of tumours is both a blessing and a curse: molecular gradients reduce therapeutic efficacy but also create unique environments that can be targeted.
Motility is the key feature of bacterial therapies that enables intratumoral targeting. Bacteria can actively swim away from the vasculature and penetrate deep into tumour tissue (FIG. 2) . Because bacteria are complex living organisms that can acquire energy from their environment, their transport is not entropically limited. This contrasts with the concentration of passive molecules, which drops as a function of distance from vasculature. Because bacteria are selfpropelled, their density can be higher far from the vascular source. It has been shown that bacteria that can disperse throughout tumour tissue have a greater ability to regress tumours 14 . Salmonella have also been shown to chemotax towards molecules that are produced by dying tumour tissue 15, 16 . Salmonella contain chemoreceptors that sense small molecules in the local environment. For example, using knockout models, it has been shown that the aspartate receptor intiates chemotaxis towards viable tumour tissue; the serine receptor induces tissue penetration; and the ribose receptor directs migration towards necrotic tissue 16 . In addition to intrinsic motility, the host immune system has a crucial role in preventing bacterial dissemination throughout tumours. neutrophils have been shown to prevent bacteria from spreading from necrotic to viable tumour tissue 50 . This containment is one possible reason that attenuated Salmonella had limited success in reducing tumour growth in human trials [54] [55] [56] . Depleting host neutrophils increases tumour bacterial densities and enables spread throughout viable tumour tissue 50 .
Native bacterial cytotoxicity
Many successful experiments have shown that the natural toxicity of bacteria is sufficient to regress tumours (TABLE 1) . native bacterial cytotoxicity is caused by sensitization of the immune system and competition for nutrients 42 . Although some organisms naturally produce toxins, these are typically removed to prevent pathogenicity 14 . Much early work on bacterial therapies relied on their natural toxicity because direct genetic modification of bacteria was not possible. The ability of bacteria to regress tumours has been recognized since the early 1800s 57 .
In the time before strict antiseptic technique, tumour regression was occasionally observed following severe bacterial infection 57 . This observation led to the development of Coley's toxin, a bacterial extract that stimulates a general immune response [57] [58] [59] . Because of this early success, this approach persists in many contemporary strategies 20, 60 , which are similarly designed to stimulate immune responses (TABLE 2) . The idea that living bacteria could be anticancer therapeutic agents was first advanced in the middle of the twentieth century 6, 7 . The increased availability of antibiotics and the discovery that tumours contain anoxic regions 61 spurred multiple investigations 6, 62 that showed that Clostridium, an obligate anaerobe, could regress tumours in mice (TABLE 1) . There was sufficient enthusiasm to initiate a small clinical trial, and oncolysis was observed in three out of five patients following injection with Clostridium butyricum 63 (TABLE 3) .
More recently, Salmonella has been tested for its anticancer properties 4, 46 and, similar to Clostridium, Salmonella is naturally cytotoxic and has been shown to regress tumours when administered alone (TABLE 1) . Immunosensitization is one of the key mechanisms of Salmonella cytotoxicity; accumulation of Salmonella choleraesuis in tumours induces neutrophil infiltration and antitumour immune responses 64 . when investigated in human trials, Salmonella with a modified lipid A (strain vnP20009) was found to be non-toxic and tumour colonization was observed 55 . In dogs administered with vnP20009, tumour colonization was also observed and a complete cure was seen in 4 of the 35 animals 65 . There is also potential that Salmonella could be delivered orally to reduce toxicity. Following oral administration in mice, Salmonella preferentially accumulated in tumours and maintained its anticancer effects 66 with very low toxicity 67 . Oral delivery might be different in humans, in which bacterial escape from the gut to the circulation occurs less often than in mice 68 .
Expression of anticancer agents
Another advantage of bacterial anticancer agents is that they can be genetically modified to increase their effectiveness. Many strategies have been used (TABLES 1,2) and two major mechanisms have been studied: the direct expression of proteins that have physiological activities against tumours and the transfer of eukaryotic expression vectors into infected cancer cells. For both of these mechanisms, three categories of Figure 2 | The transport properties of bacterial therapies produce preferable drug concentration profiles. When injected systemically, bacteria (blue syringe; brown bacteria) specifically accumulate in tumours and migrate to distal regions far from the vasculature (shaded cells). these distal regions are typically hypoxic and hypoglycaemic and contain quiescent and necrotic cells. Once triggered (small arrows), bacteria begin to produce therapeutic molecules (blue ovals) that diffuse (large arrow) into viable tissue. systemically injected, passive chemotherapeutic molecules (red squares) diffuse into tumour tissue from blood vessels (large arrow). the concentration of bacterially produced molecules (blue lines on graphs) is greatest in distal tumour regions and remains constant as long as expression of these proteins continues. the concentration of chemotherapeutic molecules is greatest in systemic blood and drops as it is cleared by the liver or kidneys. Based on these profiles, bacterially produced molecules will be more cytotoxic (shown by dashed lines on the graph) in the distal regions of tumours and less systemically toxic. the profile of passive molecules is less favourable, with more systemic toxicity and less efficacy deep in tissue.
anticancer agents have been investigated: cytotoxic agents that directly kill cancer cells, cytokines that stimulate immune cells to kill cancer cells and tumour antigens that sensitize the immune system against cancer cells. Prodrug strategies have been reviewed previously 69, 70 and are not discussed here.
Cytotoxic agents. Bacterial toxins are the most obvious cytotoxic agents because these genes are native to bacterial physiology. Cytolysin A (ClyA; also known as HlyE) is a bacterial toxin that functions by forming pores in mammalian cell membranes and inducing apoptosis 18, 19 . ClyA is a native bacterial protein that is readily transported to the bacterial surface and secreted without modification 17, 18 . Multiple groups have shown that treating mice with Escherichia coli or Salmonella typhimurium that express ClyA reduces tumour growth [17] [18] [19] . Three of the cytotoxic agents are members of the TnFα family: FAS ligand (FASl), TnF-related apoptosis-inducing ligand (TRAIl) and TnFα [23] [24] [25] [26] [27] . These proteins selectively induce apoptosis through death receptor pathways, which activate caspase 8 and caspase 3, an important apoptotic mediator 23 . All three are selectively cytotoxic to cancer cells compared with normal cells 23, 24 .
FASl specifically induces apoptosis in cells that possess the FAS receptor 24 . TnFα and TRAIl have been shown to be cytotoxic towards colon, breast, lung, prostate, renal, ovarian, bladder, glioma and pancreatic tumours 23, 71 . when systemically administered as protein drugs, all three members of this family have two deficiencies that are overcome by bacterial delivery: hepatotoxicity and a short circulatory half-life 23, [25] [26] [27] . Producing these proteins in situ would maintain a higher continual concentration in tumours compared with delivery to the circulatory system (FIG. 2) , and would reduce the systemic toxicity that is associated with their administration as small molecules. FASl is also immunologically active: it attracts tumour-rejecting granulocytes, induces interleukin-23 (Il-23) production by dendritic cells and stimulates the proliferation of T cells -three mechanisms that might culminate in the specific killing of cancer cells 24 .
Cytokines. Bacteria can also be engineered to deliver specific cytokines that have antitumour effects (TABLE 2) . Cytokines induce immune cells to clear tumours by stimulating multiple mechanisms, such as immune cell activation, proliferation and migration. when administered as a small molecule, Il-2 activates the cytolytic function of natural killer and lymphokine-activated killer cells 72 and promotes lymphocyte proliferation 73 . Similar to Il-2, Il-18 (also known as interferon-γ (IFnγ)-inducing factor) induces T cell and natural killer cell proliferation and enhances their production of cytokines 74 . Il-18 also suppresses angiogenesis by inhibiting fibroblast growth 74 . CCl21 controls the migration of immune cells and may prevent tumour-induced immunosuppression 21 . lIGHT (also known as TnFSF14) is a TnF family cytokine that is homologous to lymphotoxin, which induces dendritic cell growth 20 . Il-2 is the most extensively studied bacterially delivered cytokine 72, 73, [75] [76] [77] [78] [79] [80] . Reports describing Il-2 delivery by Salmonella were the first to suggest that this genus could be effectively used as an anticancer agent 73, 80 . Oral administration of Salmonella expressing Il-2 has been shown to function prophylactically and prevent tumour formation 79 . Despite multiple anticancer effects, Il-2 and Il-18 have had limited success as chemotherapeutics because of severe systemic toxicity [72] [73] [74] . Similar to the TnFα family agents, local production of these cytokines in tumours would limit toxicity while stimulating tumour infiltration by lymphocytes 72 . Treatment with Salmonella that express lIGHT or CCl21 has been shown to induce leukocyte and neutrophil infiltration and inhibit tumour growth 20, 21 .
Tumour-specific antigens and antibodies. The expression of tumour-specific antigens is another bacterial strategy that uses the host immune system (TABLE 2) . It functions by sensitizing immune cells and preventing the formation of tumours that present those antigens 22, 60, 81, 82 . For example, RAF1 (also known as c-RAF) is a transcription factor that is upregulated in many tumours 22 ; prostate-specific antigen (PSA) is upregulated in many prostate tumours 60 ; and nY-ESO-1 (also known as CTG1B) is a germ cell protein often expressed by tumour cells 82 . To induce a more efficient immune response, PSA has been fused to cholera toxin subunit B (CtxB), a mucosal adjuvant 60 . Alternatively, a nonspecific immune response can be induced by the expression of a potent antigen, such as canine parvovirus (CPv) 81 . To facilitate interaction with immune cells, different protein secretion systems have been used; for example, RAF1 and CtxB-PSA were fused to the α-haemolysin secretion signal 22, 60 and CPv was bound to OmpA, a membrane protein that forms outer membrane vesicles 81 . Because these strategies rely on a systemic immune response, it is not necessary for these antigens to be expressed in tumours 82 . Also, because the response is retained by the immune system, these bacterial therapies could be used for prevention or as treatment vaccines.
Alternatively, bacteria can be engineered to express single-chain antibodies to inhibit proteins that are necessary for tumour cell function. For example, Clostridium novyi has been modified to express single-chain antibodies that bind the hypoxia inducible factor 1α (HIF1α) antigen 83 . HIF1α is an important target because it is associated with resistance to radiotherapy and chemo therapy and poor clinical outcome 83 . Preliminary studies have shown that bacterially produced antibodies bind the HIF1α epitope 83 .
Gene transfer. The ability of therapeutic bacteria to transfer genetic material to mammalian cells was first reported in 1995, when it was shown that Shigellae could transfer plasmid DnA into baby hamster kidney cells 84 . Soon after, it was shown that Salmonella could also be used for transkingdom DnA transfer 85, 86 . These reports generated considerable enthusiasm for using bacteria (specifically Salmonella) to transfer the genes for cytotoxic and immunological agents into cancer cells (TABLE 2) . Compared with direct expression, this approach has benefits as well as drawbacks. Gene transfer, which uses more permanent mammalian systems, may produce stronger, more stable expression. However, the expression of the transfer genes might be harder to control 87 ; it could be limited by poor transfer efficiency; transferred genes may be heterogeneously distributed in tissues; and genes could also transfer to tissues other than those that they are targeted towards. Many of the same strategies have been attempted with gene transfer as with direct expression: cytotoxic agents, cytokines and tumour antigens (TABLE 2) . Two early reports describe the transfer of the anti-angiogenic genes endostatin 44 and thrombospondin 1 (REF. 51 ), which kill tumours by preventing new blood vessel formation and cutting off the nutrient supply 44 . Although direct administration of endostatin to patients with cancer showed only minimal antitumour activity, transfer of endostatin from Salmonella reduced microvessel density, decreased vascular endothelial growth factor (vEGF) expression and slowed tumour growth in mice 44 . Using a similar strategy to direct expression, the reduction of tumour growth was shown by transferring the genes encoding TRAIl and SMAC (also known as DIABlO) into tumour cells from Salmonella
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. The antitumour effects of three cytokines and growth factors have been explored by bacterial gene transfer: Il-12 (REFS 89-91), granulocyte/macrophage colony-stimulating factor (GM-CSF) 90 and FlT3l
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. Similar to bacterially expressed cytokines, these molecules stimulate natural killer cells, T cells and dendritic cells [89] [90] [91] . In addition, Il-12 induces IFnγ production and GM-CSF activates neutrophils and macrophages to lyse tumour cells 90 . when expressed together, Il-12 and GM-CSF significantly reduce tumour growth in mice, while limiting the systemic toxicity that is associated with systemic cytokine injection 90 . The transfer of genes for two tumour antigens has been shown to be effective at reducing tumour growth in mouse models: α-fetoprotein (AFP) and vEGF receptor 2 (vEGFR2; also known as FlK1) [93] [94] [95] . Antibodies against AFP, an embryonic protein that is overexpressed in hepatocellular carcinoma and is not present in normal adult tissue, prevents the formation of liver and colon tumours 95 . vEGFR2 is an endothelial cell receptor that controls angiogenesis, and antibodies against vEGFR2 have been shown to prevent angiogenesis and tumour growth in glioblastoma 94 and lung cancer 93 models.
Gene silencing. A complementary strategy to the bacterial induction of gene expression is gene silencing. Silencing is achieved by transferring plasmids encoding small hairpin RnAs (shRnA) from Salmonella into cancer cells 96, 97 . Gene-specific shRnAs are processed by the enzyme Dicer into small interfering RnAs (siRnAs) that induce the degradation of target mRnAs 96 . To date, two genes have been silenced using this technique, signal transducer and activator of transcription 3 (Stat3) 96 and Bcl2 (REF. 97 ). Both factors inhibit apoptosis, and STAT3 promotes cancer cell growth. Overexpression of these factors has been associated with many tumour types, including prostate cancer and malignant melanoma 96, 97 . Silencing of Stat3 has been shown to prevent prostate tumour and metastasis formation in mice 97 .
Gene-triggering strategies
The control of gene expression is crucial for managing the timing and location of drug production. The incorporation of specific promoter sequences upstream of genes that encode anticancer proteins enables the control of transcription by external signals. Precise triggering of expression can be used to induce greater intratumoural effects while minimizing systemic toxicity 23 . Some gene products require tighter control than others; for example, cytotoxic molecules and cytokines that are known to be toxic cannot be constitutively expressed. Tumourspecific antigens do not need to be expressed in tumours, and so the tight control of the genes expressing these antigens is not necessary 82 . There are two categories of gene-triggering strategies: extracellular triggers and environmental sensors (TABLE 2) . Three external triggers have been investigated: l-arabinose, salicylate and γ-irradiation (FIG. 3) . The pBAD system uses the regulatory protein AraC to respond to extracellular l-arabinose 17, 28, 29 and is very tightly regulated 98 . The salicylate system is also tightly regulated and its cascade amplifies gene expression, producing induction ratios of 20-150-fold in vitro 99 . Both l-arabinose and salicylate are suitable and non-toxic biological triggers. In mouse models, it has been shown that intravenous administration of l-arabinose can activate gene expression in colonized tumours 29 . The RecA mechanism uses γ-irradiation as a trigger of gene expression (FIG. 3) and is based on the SOS DnA repair system 23, 26, 27, 30 . Irradiation has a major advantage over molecular triggers because it can directly penetrate tumour tissue and is not restricted by diffusion limitations 2 . γ-irradiation causes DnA damage and activates RecA 23 , which promotes autoproteolysis of the repressor lexA. The lysis of lexA, a repressor of the recA promoter, induces gene expression. This system is amplified by selfinduction of RecA when lexA is cleaved. To reduce basal expression and increase radiation responsiveness, nuyts et al. 100 showed that adding an extra Cheo box into the recA promoter increased expression tenfold.
To date, all environmental triggering strategies have been designed to sense hypoxia using the fumarate and nitrate reduction (FnR) regulator 19, 101 (FIG. 3) .
FnR is an oxygen-responsive transcription factor that is naturally present in Salmonella 19, 101, 102 . In the absence of oxygen, iron-sulphide clusters induce the formation of FnR homodimers that bind to specific DnA sequences and promote transcription 19, 101 . In the presence of oxygen, the clusters and FnR homodimers disassemble, reducing transcription. Two artificial promoters have been developed that contain FnR-binding sites: FF+20* (REF. 19 ) and hypoxia inducible promoter 1 (HIP1) 101 (TABLE 2). These two promoters were created by random 19 and directed 101 mutagenesis to amplify expression in hypoxia and reduce expression in normoxia 19 . To identify bacterial promoters that could be used LexA RecA in environmental-triggering strategies, Arrach et al. 103 developed a reporter system that they tested in tumour-bearing mice. The two most active promoters, pflE and ansB, both contained FnR-binding sites and are known to be oxygen dependent 103 . These experiments did, however, identify other promoters that were not oxygen dependent and might rely on alternative environmental triggers.
Detection
Being able to locate colonized bacteria is clinically important because it enables the detection of obscured tumours and metastases. Four different strategies have been implemented to identify bacteria in tumours: bioluminescence, fluorescence, magnetic resonance and positron emission (TABLE 2) . Bioluminescent bacteria are generated by transformation with plasmids containing the luxCDABE operon from Photobacterium leiognathi 5, 17, [104] [105] [106] , and fluorescent bacteria are generated by transformation with plasmids containing the gene for green fluorescent protein 5, 31, 32 . Both of these mechanisms have proved to be very efficient at identifying tumours in mice using whole-mouse imaging 5, 17, 31, 32, [104] [105] [106] . These light-based mechanisms might have limited clinical applications, however, because of the poor penetration of visible light through tissue.
Alternatively, magnetotactic bacteria could be injected and detected by MRI. For example, Magnetospirillum magneticum produces magnetite particles and has been shown to accumulate in tumours 33 . For improved tumour targeting, the genes for magnetite production could be transferred into other bacterial strains 33 . Two different methods that have been used to detect bacteria with PET are expression of an exogenous viral tyrosine kinase 34, 35 and reliance on endogenous protein kinases 36 . when herpes simplex thymidine kinase (HSv1-TK) is expressed in Salmonella, it selectively phosphorylates and traps the detectable marker 2′-fluoro-1-β-darabino-furanosyl-5-iodouracil (FIAU) 35 . Alternatively, the endogenous protein kinases of E. coli nissle 1917 have been shown to phosphorylate and trap 36 . Both these methods have successfully been shown to identify bacteria accumulated in mouse tumours [34] [35] [36] .
Conclusions and future perspectives
Recently, many experiments have shown that bacterial therapies can successfully regress tumours and promote survival in mice. However, numerous challenges remain before bacteria can be used in the clinic, including limited drug production, intrinsic bacterial toxicity, targeting efficiency, genetic instability and combination with other therapies. Tuning drug production is necessary to synthesize drugs at sufficient concentrations to induce therapeutic effects but at concentrations not high enough to cause systemic toxicity (FIG. 2) . Controlling bacterial toxicity will be crucial to ensure safety and allow regulatory approval. Both Clostridium and Salmonella have been shown to be non-pathogenic in multiple animal species 46, 65 and in human trials [54] [55] [56] 63 , but any retained virulence could be problematic for immunocompromised late-stage cancer patients. variable targeting efficiency could lead to poor efficacy for large groups of patients and will affect which sites could be effectively treated with bacteria. Targeting efficacy will also play a large part in the treatment of metastatic disease because, to be effective, bacteria will have to colonize a high proportion of distal sites. Genetic instability is a potential problem because mutations could create ineffective or harmful phenotypes. The rate of mutation will specify the upper time limit that bacterial colonies could be allowed to remain in tumours. Finally, determining the correct combination of bacteria and other cancer therapies 14, 18, [107] [108] [109] [110] (TABLES 1, 2) will be crucial for creating strategies that can completely clear tumours and metastases. Solving these challenges could overcome the limitations that have previously been seen in the clinic [54] [55] [56] (TABLE 3) : reduced toxicity will increase the maximum-tolerated dose; improved targeting will increase tumour colonization; and efficient drug production will promote tumour regression.
All these challenges can be addressed using synthetic biology techniques. Rates of protein drug production can be optimized by manipulating multiple factors 111 , including gene copy number, promoter strength, optimized codons, bacterial metabolism, mRnA secondary structure 112 and synthetic ribosome-binding sites 113 . Both toxicity and targeting are affected by the immune response following injection and innate bacterial virulence. Determining which Figure 3 | Gene triggering systems. a | the pBAD system, which responds to extracellular l-arabinose, contains two components: the arabinose-sensitive protein Arac and the pBAD promoter. the constitutively expressed regulator Arac induces transcription by binding to the pBAD promoter. Arac is a positive and negative regulator of pBAD: it activates transcription in the presence of arabinose and represses transcription in its absence. b | the salicylate cascade system uses two salicylate-sensitive regulator proteins, nahr and xyls2, to maintain tight regulation. In the presence of salicylate, nahr activates transcription from the promoter Psal, leading to the expression of Xyls2. Xyls2, which is also sensitive to salicylate, activates transcription from the promoter Pm. c | the recA system senses γ-irradiation, which causes DNA damage. this damage activates recA, which induces autoproteolysis of LexA. transcription is induced when LexA, a repressor of the pRecA promoter, releases from DNA. Feed-forward regulation increases the recA concentration when the system is active. d | the fumarate and nitrate reduction (FNr) system turns on in hypoxic environments. the absence of oxygen promotes the dimerization of FNr, which induces transcription. Multiple promoters bind FNr, including FF+20*, HIP-1, pfle and ansB.
virulence factors are essential for targeting and which introduce unnecessary toxicity can be achieved by screening knockout models of the pathogenicity genes that, for example, enable the evasion of the immune system, induce uptake into cells, promote intracellular replication and stimulate cytokine synthesis 114 . Other targeting mechanisms can be enhanced by the genetic manipulation of endogenous chemoreceptors 16 , selective control of bacterial proliferation in tumours and strategies to avoid sequestration by neutrophils. Similarly, genetic stability could be enhanced by incorporating engineered genes on the bacterial chromosome and by limiting homologous recombination and horizontal gene transfer.
This moment in history is a turning point for bacterial therapies. The preliminary proof-of-concept experiments have demonstrated the vast capacity of bacteria for treating cancer and have illustrated the large number of effective tools that these robot factories possess. The ultimate bacterial therapy will consist of a collection of strains designed for specialized purposes rather than a single perfect strain. Successful treatment could use these strains cooperatively and in combination with molecular chemotherapy: a detectable facultative anaerobe could be used for diagnosis; an engineered immunogenic stain could be used to sensitize the immune system; an obligate anaerobe could be used to treat inoperable primary tumours; and a motile Salmonella strain that controllably produces a cytotoxic agent could be used to treat diffuse tumours and metastatic disease. All bacterial therapies will be in used in combination with other therapeutics 14, 18, [107] [108] [109] [110] (TABLES 1,2), which will have a synergistic effect: small molecules would kill cancer cells close to blood vessels and bacteria would kill cells far from vessels (FIG. 2) . The greatest strength of bacterial therapies is their genetic flexibility, which enables tuning for individualized therapy, targeting to multiple tumour sites and the precise control of cytotoxicity. Once perfected, anticancer bacteria are expected to be an essential clinical tool, able to carry out functions that are unachievable by other therapies, and which can detect, prevent, and treat tumours and metastases.
